Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

AIDS

Volumn 20, Issue 10, 2006, Pages 1401-1406

  Winston, Alan ^a,d   Back, David ^b   Fletcher, Carl ^a   Robinson, Lesley ^b   Unsworth, Jennifer ^b   Tolowinska, Izabela ^a   Schutz, Malte ^c   Pozniak, Anton L ^a   Gazzard, Brian ^a   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Healthy volunteers; HIV; Omeprazole; Pharmacokinetics; Protease inhibitors

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; OMEPRAZOLE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; RITONAVIR; SAQUINAVIR;

EID: 33745456982     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000233573.41597.8a     Document Type: Article

References (35)

1. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-626.
2. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005; 56:1-5.
3. Luber A, Garg V, Gharakhanain S. Survey medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [abstract P294].
4. Rublein JC, Donovan BJ, Hollowell SB, Min SS, Theodore D, Raasch RH, et al. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects. Forty-third Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2003 [abstract A-1611].
5. van Heeswijk R, Sabo JP, Cooper C, Cameron W, MacGregor TR, Elgadi M, et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200 mg bid (TVP/r) and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers. Fifth International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, March 2004 [Abstract 35].
6. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. Twelfth Conference on Retroviruses and Opportunistic Infections. Boston MA, February 2005 [abstract 658].
7. Agarwala S, Eley TVC, Child M, Wang Y, Hughes E, Chung E, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. Sixth International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, April 2005 [abstract 11].
8. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005; 49:467-469.
9. Shelton M, Ford SL, Wire MB. Coadministration of esomeprazole (ESO) with fosamprenavir (FPV) has no impact on steady-state plasma amprenavir (APV) pharmacokinetics (APV10031). Sixth International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, April 2005 [abstract 24].
10. Sekar V, Hoetelmans R, De Marez T, De Pauw M, Vangeneugden T, Godderis F, et al. Pharmacokinetics of TMC114: effect of omeprazole and ranitidine. Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 2005 [abstract WePe3.3C13].
11. Klein C, Chiu YL, Cai Y, Beck K, King K, Causemaker S, et al. Lack of effect of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir tablet. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [poster 578].
12. Bertz RJ, Chiu Y, Naylor C, Luff K, Brun SC. Lack of effect of gastric acid reducing agents on lopinavir/r plasma concentrations in HIV infected patients. Seventh Conference on Drug Therapy for HIV Infection. Glasgow, UK, November 2004 [abstract 201].
13. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 (suppl 1):1-41.
14. Boffito M, Carriero P, Trentini L, Raiteri R, Bonora S, Sinicco A, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 2002; 50:1081-1084.
15. Hoffman La Roche Ltd, Basel, Switzerland. http://www.rocheusa.com/ products/invirase/pi.pdf Accessed 8 February 2006.
16. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005; 28:789-801.
17. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:551-557.
18. Dickinson L, Robinson L, Tjia J, Khoo S, Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;
19. Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther 2005; 22:59-65.
20. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64:5804-5811.
21. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996; 23:1491-1497.
22. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25:853-862.
23. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005; 67:1152-1160.
24. Collett A, Tanianis-Hughes J, Carlson CL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: Relevance to in vivo prediction. Eur J Pharm Sci 2005.
25. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-194.
26. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31:1-10.
27. Owen A, Chandler B, Back DJ. The implications of P-glycoprotein in HIV: friend or foe? Fundam Clin Pharmacol 2005; 19:283-296.
28. Janneh O, Owen A, Chandler B, Hartkoom RC, Hart CA, Bray PG, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19:2097-2102.
29. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 2005; 15:599-608.
30. Huisman MT, Smit JW, Crommentuyn KM, Zelser N, Wiltshire HR, Beijnen JH, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
31. Dickinson L, Back D, Chandler B, Owen A, Khoo S, Pozniak A, et al. The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. Sixth International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, 2005 [oral abstract 2.3].
32. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189:1176-1184.
33. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanic J, Siangphoe U, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56:908-931.
34. Ananworanich J, Hill A, Siangphoe U, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005; 10:761-767.
35. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.